Article
Social risk data is one of the most impactful resources a pharmaceutical company can leverage to navigate a major industry challenge: loss of exclusivity.
Loss of exclusivity (LOE) forces a strategic reckoning. The patent cliff at the heart of them goes beyond price. It’s about which markets matter, which populations to target, and which investments actually move the needle. LOE is an inevitability that makes pharmaceutical companies face a choice: compete on volume and price against generics or compete on strategic precision to improve outcomes.
Knowing what to do, and how to do it, requires understanding social risk.
The current approach has most pharmaceutical companies optimizing around clinical variables and traditional demographics data. Unfortunately, this can miss the differentiation in which populations are driving outcomes and the ones driving costs. Social determinant of health (SDOH) data reveals the gap between who responds to therapy and who doesn't, where market access barriers exist, and where reimbursement risk concentrates, and, critically, why. For companies navigating loss of exclusivity, social risk intelligence is an unparalleled competitive advantage. It takes them far beyond the current practice and into another level of understanding.
Our approach to SDOH data delivers the necessary path forward to remain strategic with investment even in constrained-revenue environments.
SDOH Data Drives R&D and Pipeline Strategy
Understanding social risk in your patient population informs which programs survive. You can assess therapy performance across populations and identify where clinical efficacy translates to real-world impact.
SDOH Data Supports Market Access and HEOR
Payers increasingly require evidence of outcomes and value across diverse populations. Social risk stratification lets you model reimbursement scenarios, anticipate coverage decisions, and build health economic arguments grounded in population reality. Understanding and acting on social risk builds the foundation for competitive value-based discussions.
Real-World Evidence and Patient Support Services
SDOH data closes the gap between what you observe in trials and what happens in practice. Patient discontinuation, non-adherence, and program engagement aren't random, they all correlate with social barriers. Targeting support services where they actually matter reduces overhead and improves outcomes. With our help, your post-LOE commercialization team can deploy resources against evidence, not guesses.
It all works because Socially Determined brings pharmaceutical companies unique, proprietary social risk models. We don't resell third-party data; we measure social components that actually drive outcomes and costs in healthcare. That precision means your strategic decisions, from R&D to market access to patient support, are anchored in the same population intelligence your payer and provider partners use.
For pharmaceutical companies under LOE pressure, that alignment matters. It’s a new, effective way to reduce the friction between your strategic priorities and the markets where you're actually winning.
The companies that win after LOE are the ones that stop competing on volume and start competing on strategy that aims to improve outcomes. SDOH data is how you can differentiate and make that shift.
If you’d like to learn more, we’ll be at Fierce Pharma Week later this month in Philadelphia. If you see us, say hello. We want to hear your challenges because, frankly, our team loves nothing more than finding out what we can do for you today but also offer unique solutions to your unique problems.